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Impact: Ovarian cancer is increasingly recognized as a heterogeneous disease, but risk factor differences 
across subtypes are not well understood. We present a detailed prospective investigation on reproductive and 
hormone-related risk factors for borderline tumors and epithelial ovarian cancer by main histologic subtypes 
and the dualistic pathway (type I and type II tumors). To our knowledge, our investigation is the first 
prospective study on reproductive and hormone-related risk factors for ovarian cancer by the dualistic 
pathway.  
  
Abstract  
Whether risk factors for epithelial ovarian cancer (EOC) differ by subtype (i.e., dualistic pathway of 
carcinogenesis, histologic subtype) is not well understood; however, data to date suggest risk factor 
differences. We examined associations between reproductive and hormone-related risk factors for EOC by 
subtype in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Among 334,126 
women with data on reproductive and hormone-related risk factors (follow-up: 1992-2010), 1,245 incident 
cases of EOC with known histology and invasiveness were identified. Data on tumor histology, grade, and 
invasiveness, was available from cancer registries and pathology record review. We observed significant 
heterogeneity by the dualistic model (i.e., type I [low grade serous or endometrioid, mucinous, clear cell, 
malignant Brenner] vs. type II [high grade serous or endometrioid]) for full-term pregnancy (phet=0.02). Full-
term pregnancy was more strongly inversely associated with type I than type II tumors (ever vs. never: type I: 
Relative Risk (RR) 0.47 [95% confidence interval (CI): 0.33-0.69]; type II, RR: 0.81 [0.61-1.06]). We 
observed no significant differences in risk in analyses by major histologic subtypes of invasive EOC (serous, 
mucinous, endometrioid, clear cell). None of the investigated factors were associated with borderline tumors. 
Established protective factors, including duration of oral contraceptive use and full term pregnancy, were 
consistently inversely associated with risk across histologic subtypes (e.g., ever full-term pregnancy: serous, 
RR: 0.73 [0.58-0.92]; mucinous, RR: 0.53 [0.30-0.95]; endometrioid, RR: 0.65 [0.40-1.06]; clear cell, RR: 
0.34 [0.18-0.64]; phet=0.16). These results suggest limited heterogeneity between reproductive and hormone-
related risk factors and EOC subtypes. 
  
  
Introduction 
Reproductive and hormone-related risk factors for epithelial ovarian cancer (EOC) have been 
extensively investigated (reviewed in ref 1). However, EOC is increasingly recognized as a heterogeneous 
disease and risk factor differences across EOC subtypes, such as the recently proposed dualistic pathway of 
ovarian carcinogenesis (i.e., type I, type II1,2) and main histologic subgroups (i.e., serous, mucinous, 
endometrioid), are not well understood.  
The dualistic model of ovarian carcinogenesis suggests that EOC develops by two pathways:2 type I 
tumors are less aggressive and are thought to develop from defined precursor lesions (i.e. borderline tumors, 
endometriosis), while type II tumors are more aggressive, rapidly metastasize, and have no well-defined 
precursor lesion within the ovary.3 Type I EOC includes low grade serous and endometrioid EOC, as well as 
mucinous, clear cell, and malignant Brenner tumors, whereas type II tumors are primarily high grade serous or 
endometrioid EOC. To our knowledge, only one prior study has investigated reproductive and hormone-
related risk factors by the dualistic pathway; this study observed significant heterogeneity in risk factors 
between type I and type II tumors.4 For example, parity exerted a stronger protective effect against type I 
tumors, whereas associations between duration of oral contraceptive (OC) use and breastfeeding duration were 
stronger for type II tumors.4 These findings have not yet been replicated. 
Prior studies suggest risk factors for epithelial ovarian cancer may differ by histologic subtype.1,4-13 
For example, a collaborative reanalysis of 45 epidemiologic studies found the risk reduction afforded by OC 
use was evident for serous, endometrioid and clear cell, but not mucinous, tumors13 and an analysis in the 
Ovarian Cancer Cohort Consortium (OCAC) found a positive association between body mass index (BMI) and 
risk of invasive endometrioid, mucinous and clear cell, but not high grade serous, tumors.12 However, 
heterogeneous associations between BMI and EOC histologic subgroups have not been observed in all 
studies.14 The extent to which reproductive and hormone-related factors impact risk differentially by histologic 
subtype remains unclear. 
An improved understanding of heterogeneity in risk across EOC subtypes will ultimately improve our 
understanding of the etiology of this lethal disease. Therefore, we present a detailed investigation of 
reproductive and hormone-related risk factors and EOC by the dualistic pathway of carcinogenesis and major 
histologic subtypes in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. 
 
  
Methods 
 The EPIC cohort was established between 1992-2000 at 23 centers in 10 countries: Denmark, France, 
Germany, Greece, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom. Details of the 
study design have been published previously.15,16 Briefly, more than 500,000 men and women between the 
ages of approximately 25-75 years of age were enrolled; participants provided detailed information on diet and 
lifestyle, including data on reproductive and menstrual history, hormone use, and medical history. In all 
countries except France, Germany, and Greece, as well as the center of Naples, Italy, follow-up is based on 
record linkage; the end of follow-up was the date of last follow-up for cancer incidence and vital status (2004-
2009). In France, Germany, Greece, and Naples, Italy, a combination of active follow-up with participants and 
their next-of-kin, and outcome verification with medical and health insurance records was used. Vital status is 
available from mortality registries. End of follow-up for France, Germany, Greece, and Naples, Italy, was the 
earliest of date of last contact, cancer diagnosis, or death (2005-2010). All subjects provided written informed 
consent. The Institutional Review Boards of the International Agency for Cancer Research and the local ethics 
committees approved the study. 
 
Study Population and Case Ascertainment 
 Participants were excluded if they reported history of prior cancer at recruitment (except non-
melanoma skin cancer), had incomplete baseline data, or reported bilateral oophorectomy at baseline, leaving a 
study population of 334,225 women. We additionally excluded women missing data on all investigated 
reproductive and hormone-related risk factors (n=99). Our final study population included 334,126 women. 
Cases were defined as women diagnosed after recruitment with an incident epithelial borderline tumor (C569) 
or invasive ovarian (C569), fallopian tube (C570) or peritoneal cancer (C480, C481, C482, C488) according to 
the International Classification of Diseases for Oncology (ICD) O–3 topography codes. The majority of 
tumors identified were ovarian (borderline: 100%, n=106; invasive: 93%, n=1063), with a relatively small 
proportion of fallopian tube (3.4%, n=42) and peritoneal (2.7%, n=34) malignancies included. Data on 
invasiveness, histology, cancer stage, and tumor grade was available from cancer registries and pathology 
record review. A total of 1,245 EOC cases with data on tumor histology and invasiveness were identified. 
Grade information, used for type I and type II classification, was complete for 56% of cases (n=670).  
  
Invasive tumors were classified as type I or type II as described by Shih and Kurman.2 Type I tumors 
were defined as low-grade (grade 1, well differentiated) tumors of serous and endometrioid histology, as well 
as mucinous, clear cell and malignant Brenner tumors; type II tumors include high-grade (grade 2 or 3, 
moderately or poorly differentiated) serous and endometrioid tumors, as well as undifferentiated and 
malignant mixed Mullerian tumors.  
 
Exposure Assessment 
 Data on age at menarche, age at menopause, parity and number of full-term pregnancies, breast 
feeding, menstrual cycle regularity, OC use and duration, menopausal hormone replacement therapy (MHT) 
use, and hysterectomy were collected at baseline using standardized questionnaires. Height (cm) and weight 
(kg) were measured according to standardized procedures, except for the Oxford cohort, the Norwegian 
cohort, and part of the French cohort, where height and weight were predominantly self-reported.17 For 
participants from the Oxford cohort, where only self-reported data were available, linear regression models 
were used to recalibrate values using age-specific measurements from subjects with both measured and self-
reported body measures. These measures were used to calculate body mass index (BMI; kg/m2). 
 
 
Statistical Analysis 
We used Cox proportional hazards models to estimate the association between reproductive and 
hormone-related factors and risk of overall invasive EOC (n=1,139) and borderline tumors (n=106), as well as 
invasive EOC by main histologic subtypes (serous (n=631), mucinous (n=79), endometrioid (n=131), and 
clear cell (n=57)), and type I (n=184) and type II (n=480) status. Age in years was the underlying time scale, 
and all analyses were stratified by age and study center. Main exposure variables were categorized as follows: 
age at menarche: <13, 14, >15 years; age at menopause: <48, 49-50, 51-54, >55 years; full-term pregnancy: 
yes/no; number of full-term pregnancies: 0, 1, 2, 3+; breastfed: yes/no; menstrual cycle regularity: < 26 days, 
27-29 days, 30+ days, none or irregular; OC use: yes/no; OC duration: never user, < 1 year, 1-4 years, 5-9 
years, >10 years; hysterectomy: yes/no; HRT use: yes/no; BMI: normal weight (<25 kg/m2), overweight (25-
30 kg/m2), obese (≥30 mg/m2). Tests for trend were conducted by modelling continuous variables. 
  
Covariates for statistical adjustment were identified a priori. All analyses were adjusted for OC use 
(ever/never), HRT use (ever/never), age at menopause (continuous; pre-/perimenopausal assigned median age 
at menopause), menopausal status at baseline (pre- or perimenopausal/postmenopausal), and full-term 
pregnancy (ever/never), except when the variable was the main effect. Missing values for HRT use (7.8%) 
were coded in a “missing” category for statistical adjustment. Missing values for OC use (3.2%) were coded as 
“never” users; given the low prevalence of missing data for this covariate, we were unable to use separate 
“missing" category for statistical adjustment. Differences in risk associations by histologic subtype and 
borderline and type I/II status were assessed using the data augmentation method proposed by Lunn and 
McNeil.18 Heterogeneity (phet) between subtypes was assessed using a likelihood ratio test comparing models 
assuming the same association between exposure and EOC across all outcomes (e.g., tumors of serous, 
mucinous, endometrioid, and clear cell histology as a single outcome) to one assuming different associations 
for each subtype (i.e., each histology considered individually as an outcome). In analyses by the dualistic 
model, heterogeneity was assessed between type I and type II tumors, as well as across borderline, type I and 
type II tumors. Results were similar, therefore p for heterogeneity between type I and type II tumors is 
presented.  
 We investigated the major individual components associated with duration of ovulatory lifespan and 
EOC risk.19 These analyses included ages at menarche and menopause, duration of OC use, and duration of 
full-term pregnancies (number of full-term pregnancies *0.75), mutually adjusted and as a composite variable 
to estimate total duration of ovulatory lifespan. We further examined associations between number of full-term 
pregnancies, age at first and last pregnancy, and time since last pregnancy in mutually adjusted models 
investigating risk associations among parous women. We used the approach described by Heuch et al.20 to 
ensure that observed risk estimates were not biased by multi-collinearity. In these analyses, nulliparous women 
were assigned to the reference category of age at first and last pregnancy, and time since last pregnancy, and 
indicator variables for parity were included in the model such that effect estimates reflect risk among parous 
women. Sensitivity analyses were conducted excluding women diagnosed with fallopian tube or peritoneal 
cancers. 
 P-values <0.05 were considered statistically significant; all p-values were two-sided. All analyses 
were conducted in SAS 9.3 (Cary, NC). 
 
  
Results 
Baseline characteristics by tumor invasiveness and the dualistic model are presented in Table 1. 
Briefly, women who remained free of EOC were somewhat younger at recruitment than those diagnosed with 
invasive disease during follow-up (median age at recruitment, non-cases: 51 years; invasive cases: 55 years), 
and a higher proportion of women subsequently diagnosed with invasive EOC were postmenopausal at 
recruitment (63%), relative to women diagnosed with borderline tumors (33%) and to women who remained 
free of EOC (45%). As expected, the majority of both borderline (58%) and invasive (55%) tumors were of 
serous histology. A total of 81% of type II tumors were serous, whereas type I tumors were predominantly of 
mucinous (43%) and clear cell (31%) histology. 
Ever full-term pregnancy was differentially associated with risk across subgroups defined by type I 
and type II status (type I vs. II: ever full-term pregnancy, phet=0.02) (Table 2). We observed a significant 
inverse association between ever full-term pregnancy and type I tumors (ever vs. never full-term pregnancy: 
Relative Risk (RR): 0.47 [95% Confidence Interval (CI) 0.33-0.69]), and no association with type II or 
borderline tumors (type II, RR: 0.81 [0.61-1.06]; borderline, RR: 1.12 [0.59-2.13]). There was no statistically 
significant heterogeneity by type I and type II status for any of the other investigated exposures. However, age 
at menopause was significantly associated with type I tumors (>55 vs. ≤48 years, RR: 2.71 (1.17-6.30), 
ptrend=0.01; phet=0.21) and only suggestively associated with type II tumors (>55 vs. ≤48 years, RR: 1.57 (0.99-
2.47), ptrend=0.04). Duration of OC use and number of full-term pregnancies were inversely associated with 
both type I and type II, but not borderline, tumors (e.g., >10 years vs never use of OC: borderline, RR: 0.75 
[0.35-1.61], ptrend=0.22; type I, RR: 0.54 [0.31-0.94], ptrend=0.01; type II, RR: 0.71 [0.51-0.97], ptrend=0.01; 
phet=0.22). 
We additionally examined exposures related to total ovulatory lifespan (ages at menarche and 
menopause, OC use, and pregnancy) in mutually adjusted models (Table 3). We observed no heterogeneity in 
associations by the dualistic model (all phet values ≥0.09). However, age at menopause was only significantly 
associated with type I tumors (per year younger age at menopause, RR: 0.92 [0.86-0.98], whereas duration of 
OC use was only associated with type II tumors (per year of OC use, RR: 0.97 [0.96-0.99]). Risk per year of 
being pregnant and total ovulatory life span were associated with both type I and type II tumors (per year 
reduction in ovulatory lifespan: type I, RR: 0.95 [0.92-0.98]; type II, RR: 0.97 [0.96-0.99]; phet=0.17). We 
repeated these analyses restricted to women postmenopausal at recruitment, given that the data on reproductive 
  
history on these women was more complete (i.e., age at menopause was known, no additional pregnancies). 
Results were somewhat attenuated after restricting the analysis to women postmenopausal at recruitment (i.e., 
per year reduction in ovulatory lifespan, postmenopausal women, type I RR: 0.96 [0.92-1.00]; type II RR: 0.99 
[0.97-1.00]). 
We observed no heterogeneity in the associations between evaluated risk factors and invasive EOC by 
main histologic subgroups (serous, mucinous, endometrioid, and clear cell; Table 4). While the heterogeneity 
between subgroups was not statistically significant, evaluated risk factors were associated with risk of 
individual EOC histologic subgroups. For example, duration of OC use was only significantly associated with 
reduced risk of serous tumors (e.g., OC use ≥10 years vs. never user, RR: 0.61 [0.46-0.82], ptrend<0.01, 
phet=0.86), older age at menopause was only associated with risk of endometrioid and clear cell tumors (≥55 
vs. ≤48 years, endometrioid: RR: 3.56 [1.63-7.76], ptrend=0.01; clear cell: RR: 2.27 (1.45-27.1), ptrend=0.03; 
phet=0.09), and ever full-term pregnancy was significantly inversely associated with serous (RR: 0.73 [0.58-
0.92]), mucinous (RR: 0.53 [0.30-0.95]), and clear cell tumors (RR: 0.34 [0.18-0.64]), but not endometrioid 
(RR: 0.65 [0.40-1.06]; phet=0.16). Ever use of HRT was only significantly associated with serous and 
endometrioid tumors. 
We observed no heterogeneity by histologic subgroup in analyses examining factors related to 
ovulatory lifespan (all phet≥0.10; Table 5). However, older age at menarche was associated with reduced risk of 
clear cell tumors (per year older age at menarche, RR: 0.77 [0.63-0.95]), while younger age at menopause was 
associated with reduced risk of both endometrioid and clear cell tumors (endometrioid: per year younger age at 
menopause, RR: 0.93 [0.87-0.99]; clear cell: RR: 0.88 [0.78-0.99]). Duration of OC use was associated with 
serous tumors (per year OC use, RR: 0.97 [0.95-0.98]). Pregnancy duration was associated with serous, 
endometrioid, and clear cell tumors (per year of being pregnant: serous, RR: 0.85 [0.77-0.94]); endometrioid, 
RR: 0.78 [0.62-0.98]; clear cell, RR: 0.56 [0.38-0.81]), as was total ovulatory lifespan (per year reduction of 
ovulatory lifespan: serous, RR: 0.97 [0.96-0.98]); endometrioid, RR: 0.96 [0.93-0.99]; clear cell, RR: 0.91 
[0.85-0.97]). None of the investigated variables were associated with mucinous tumors. Results were 
attenuated after restricting the analysis to women postmenopausal at recruitment, except for a strengthened 
positive association between delayed age at menarche and risk of mucinous tumors (n=40; RR: 1.34 [1.08-
1.67]). The association between total ovulatory lifespan and the histologic subtypes was heterogeneous 
(phet=0.02) in analyses restricted to postmenopausal women. 
  
 We analysed the associations between the following pregnancy-related variables and risk among 
parous women in mutually adjusted models: number of full-term pregnancies, age at first and last pregnancy, 
and time since last pregnancy. We observed significant heterogeneity in the associations between age at first 
full-term pregnancy and type I and II tumors (p=0.02; Supplemental Table 1). However, the individual RRs 
were not statistically significant (age at first full-term pregnancy ≥30 vs. <25 years: type I, RR: 0.73 [0.35-
1.52], ptrend=0.17; type II, RR: 1.37 [0.92-2.05], ptrend=0.03). We observed no heterogeneity in the associations 
between the examined pregnancy-related variables by the examined histologic subtypes (Supplemental Table 
2). None of the pregnancy-related variables were significantly associated with the EOC subgroups, with the 
exception of a significant positive association between time since last pregnancy and serous tumors (>30 vs. 
≤20 years since last full-term pregnancy, RR: 1.64 [1.05-2.54], ptrend=0.09). 
We conducted sensitivity analyses restricted to ovarian tumors (C569; i.e., excluding fallopian tube 
and peritoneal tumors). This resulted in exclusion of 2 type I and 36 type II tumors from analyses by the 
dualistic pathway, and 46 serous, 1 mucinous, 4 endometrioid, and no clear cell tumors from analyses by 
histology. Results including all cases were very similar to those restricted to ovarian tumors, both in analyses 
by the dualistic pathway and by histologic subtype. For example, ever vs. never full-term pregnancy was 
associated with a 53% reduction in risk of type I EOC when all cases were included, and a 54% reduction in 
risk when restricted to ovarian type I cases (all type I, RR: 0.47 [0.33-0.69]; ovarian type I, RR: 0.46 [0.32-
0.67], with comparable results for type II EOC (all type II, RR: 0.81 [0.61-1.06], ovarian type II, RR: 0.78 
[0.59-1.04]; phet comparing type I vs. II: all cases =0.02, ovarian cases=0.03. Results were similar in analyses 
by histology (e.g., ever vs. never full-term pregnancy: all serous, RR: 0.73 [0.58-0.92]; ovarian serous, RR: 
0.71 [0.56-0.89]; all mucinous, RR: 0.53 [0.30-0.95]; ovarian mucinous, RR: 0.52 [0.29-0.93]; all 
endometrioid, RR: 0.65 [0.40-1.06]; ovarian endometrioid, RR: 0.63 [0.40-1.06]).  
 
Discussion 
We observed limited heterogeneity in risk between reproductive and hormone-related factors and 
epithelial ovarian cancer subtypes in this large, prospective investigation. Full-term pregnancy was 
significantly inversely associated with type I tumors, but not with borderline tumors or type II EOC. 
Associations for full-term pregnancy were not significantly different across main histologic subgroups (serous, 
  
mucinous, endometrioid and clear cell tumors). In analyses considering invasive EOC as the outcome, the 
associations with established reproductive factors were confirmed (i.e., parity, OC use). 
The prevailing assumption that ovarian cancer originates in the ovary has been supplanted, with 
emerging data suggesting that many “ovarian” cancers originate in the fallopian tube. The recently proposed 
dualistic pathway of ovarian carcinogenesis suggests two distinct pathways. This model posits that type I 
tumors (predominantly low-grade serous) arise from precursor lesions such as borderline tumors or 
endometriosis, generally display KRAS, BRAF, or PTEN mutations and have low chromosomal instability, 
whereas type II tumors (predominantly high-grade serous) arise as aggressive neoplasms, and harbour TP53 
mutations and exhibit high chromosomal instability.2,3 A proportion of both type I and type II tumors are 
hypothesized to be of extra-ovarian origin:2,3 serous ovarian carcinomas, the most common histologic subtype 
of ovarian cancer, are hypothesized to arise from serous tubal intraepithelial carcinoma (STIC) in the fimbriae 
of the fallopian tubes, mucinous tumors are suggested to originate in the colonic mucosa or endocervical 
epithelia, and clear cell and endometrioid tumors are linked to endometriosis and display characteristics of 
endometrial tissue.2,3 We hypothesized heterogeneity in risk associations given these differences between 
ovarian cancer subtypes. 
One prior investigation has evaluated reproductive risk factors for EOC by the type I/II pathways,4 and 
one additional study investigated “rapidly fatal” (within 3 years; proxy for type II) vs. “less aggressive” (proxy 
for type I) disease.21 Consistent with these prior analyses, we observed a somewhat stronger protective effect 
for ever full-term pregnancy for type I vs. type II disease and a suggestively stronger positive association 
between older age at menopause and type I vs. type II tumors. We did not replicate prior findings of 
heterogeneity suggesting stronger inverse associations for breastfeeding4 or duration of OC use4,21 with type II 
disease. However, case numbers were limited in some subgroups. Larger studies or pooled analyses 
investigating risk factors by tumor aggressiveness are needed to better characterize EOC risk. 
Parity and number of full-term pregnancies are hypothesized to impact risk of EOC via (1) reduction 
in the number of ovulatory cycles (i.e., reducing incessant ovulation),22 (2) the well-established changes in the 
hormonal milieu during gestation, and (3) the cell clearance hypothesis.23 It is plausible that pregnancy 
differentially impacts risk of type I vs. type II tumors, given the proposed different pathways leading to the 
development of these tumors. We observed a stronger association between ever full-term pregnancy and type I 
vs. type II EOC. Given that type I tumors are slower growing malignancies, it is plausible that exposure to the 
  
“cell clearance” and hormonal milieu of a single pregnancy is sufficient to afford protection against these 
tumors. Given the rapid development of type II tumors (predominantly high-grade serous), more recent 
pregnancy-associated “cell clearance”, represented by shorter time since last pregnancy, may be the most 
relevant pregnancy-related exposure for risk reduction in this subgroup. This is in line with the significant 
positive association between time since last pregnancy and serous tumors observed in this study. However, we 
did not observe significant heterogeneity across subgroups for time since last pregnancy, nor did we observe a 
significant association between time since last pregnancy and type II tumors. 
Age at menopause was suggestively more strongly associated with type I tumors in our study. Type I 
tumors are more slowly growing malignancies than type II disease and it is plausible that type I tumors are 
more sensitive to the premenopausal hormonal milieu (i.e., relatively high endogenous estrogens). To our 
knowledge, there are no data to date examining the association between circulating estrogens and ovarian 
cancer by the dualistic pathway. However, in our previous investigation on the role of androgens and EOC by 
subtype, we observed a significant positive association between androstenedione and type I EOC, and an 
inverse association for type II disease.24 Androstenedione is a precursor to estradiol, and higher 
androstenedione may represent a higher estrogen environment. Our findings are compatible with the 
hypothesis that a higher estrogen environment is differentially associated with type I vs. type II EOC.  
Epidemiologic data to date on reproductive risk factors for EOC by histologic subtype is mixed.1,4-13 A 
longer ovulatory lifespan, or higher number of cumulative ovulatory cycles, is consistently associated with 
increased risk of EOC, and has been associated with tumors of serous,4,25 endometrioid,4,25 and clear cell4 
histology, with some evidence of heterogeneity between histologic subtypes.25 Shorter total ovulatory lifespan 
was associated with lower risk of serous, endometrioid, and clear cell tumors in the current study; no 
association was observed for mucinous tumors. Serous, endometrioid and clear cell tumors originate in the 
female reproductive tract, and thus may be more directly impacted by ovulation and/or menstruation; 
mucinous tumors, which may originate in other pelvic organs, may be less susceptible to menstrual cycle 
related events. Age at menopause was only significantly associated with endometrioid and clear cell tumors in 
our analysis. Findings for endometrioid tumors are consistent with prior data linking older age at menopause 
with increased risk of both endometrioid EOC25 and endometrial carcinoma.19,26 Recent investigations in large, 
well-characterized cohorts suggest parity27 and breastfeeding25 may differentially impact risk by histologic 
  
subtype. We did not observe heterogeneity by either of these factors, though breastfeeding was suggestively 
inversely associated with serous tumors. 
Our study has important strengths and limitations. We conducted the largest prospective analysis to 
date on reproductive and hormone-related risk factors and EOC in the well-characterized EPIC cohort. 
However, sample size for several subtypes was limited. Extensive baseline data is available for EPIC cohort 
members, however, data was not available, or had a substantial proportion missing, for some EOC risk factors, 
including tubal ligation, endometriosis, and family history of breast and ovarian cancer. Further, we used 
exposure data collected at baseline for this analysis, as updated exposure data was not available; this likely 
resulted in some misclassification for exposures including parity, duration of OC use and HRT use. We expect 
any misclassification would bias our results toward the null.  
In this large, prospective study, we observed limited differences in risk in EOC subgroups defined by 
the dualistic model of carcinogenesis, with full-term pregnancy associated with plausible differences in risk of 
type I vs. type II tumors. Large, collaborative studies are needed to further our understanding of reproductive 
and hormone-related risk factors for the least common EOC subtypes. 
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Table1. Baseline characteristics of non-cases and epithelial ovarian cancer cases classified by tumor 
invasiveness and  type I / type II status (median (5th and 95th percentile) or number (percentage)): EPIC cohort 
 
Population characteristics 
Non-Cases 
(n=332,881) 
All Invasive 
(n=1,139) 
Borderline 
(n=106) 
Type I 
(n=184) 
Type II 
(n=480) 
Age at recruitment, years 51 (33-66) 55 (41-69) 49 (30-65) 53 (36-64) 54 (41-67) 
Age at diagnosis, years - 61 (47-76) 55 (37-71) 59 (41-71) 60 (47-75) 
Age at menarche, years 13.0 (11-16) 13 (11-16) 13 (11-15) 13 (11-16) 13 (11-16) 
Menstrual Cycle Regularity      
  None or Irregular 21,507 (8%) 66 (7%) 5 (6%) 10 (7%) 30 (9%) 
  ≤ Every 26 days 62,866 (24%) 245 (27%) 17 (20%) 36 (26%) 89 (26%) 
  Every 27-29 days 132,795 (51%) 433 (48%) 47 (55%) 63 (46%) 173 (50%) 
 ≥ Every 30 days 44,272 (17%) 159 (18%) 17 (20%) 29 (21%) 55 (16%) 
Ever Full-Term Pregnancy      
  No 48,170 (15%) 182 (17%) 15 (15%) 41 (24%) 63 (14%) 
  Yes 268,972 (85%) 905 (83%) 88 (85%) 130 (76%) 393 (86%) 
Ever Breastfed1      
  No  38,591 (15%) 126 (15%) 12 (15%) 23 (20%) 62 (17%) 
  Yes 213,901 (85%) 718 (85%) 69 (85%) 93 (80%) 302 (83%) 
OC use      
  No 132,434 (41%) 574 (52%) 37 (36%) 85 (48%) 223 (48%) 
  Yes 191,677 (59%) 530 (48%) 66 (64%) 91 (52%) 244 (52%) 
Duration of OC use, years2 5.0 (1-15) 4.0 (1-15) 3.0 (1-15) 3.0 (1-15) 4.5 (1-15) 
History of Hysterectomy 25,595 (9%) 94 (10%) 8 (8%) 10 (7%) 34 (9%) 
Menopausal Status      
  Premenopausal 119,047 (36%) 224 (20%) 43 (41%) 58 (31%) 96 (20%) 
  Perimenopausal 64,669 (19%) 194 (17%) 28 (26%) 35 (19%) 92 (19%) 
  Postmenopausal 149,165 (45%) 723 (63%) 35 (33%) 91 (49%) 192 (61%) 
Age at menopause, years3 50 (40-55) 50 (40-56) 48 (42-54) 50 (42-58) 50 (42-55) 
Ever postmenopausal hormone use3      
  No  81,356 (58%) 387 (58%) 21 (60%) 53 (63%) 149 (56%) 
  Yes 59,844 (42%) 284 (42%) 14 (40%) 31 (37%) 116 (44%) 
BMI, kg/m2 24 (19-33) 25 (20-34) 24 (19-34) 25 (20-34) 24 (20-33) 
Histology      
  Serous - 631 (55%) 61 (58%) 28 (15%) 390 (81%) 
  Mucinous - 79 (7%) 43 (41%) 79 (43%)  
  Endometrioid - 131 (11%)  17 (9%) 76 (16%) 
  Clear cell - 57 (5%)  57 (31%)  
  NOS - 188 (16%)    
  Other - 53 (5%) 2 (2%) 3 (2%) 14 (3%) 
1Among parous women  
2Among women reporting ever OC use 
3Among postmenopausal women 
  
  
Table 2: Reproductive and hormone-related factors and risk of borderline tumors and invasive type I and type 
II epithelial ovarian cancer: EPIC cohort, 1992-2010 
  
Borderline Type I Type II 
 (n = 106 ) (n = 184 ) (n = 480 ) 
 Reproductive 
factor 
Case 
n 
HR1 95% CI 
Case 
n 
HR1 95% CI 
Case 
n 
HR1 95% CI 
 Age at Menarche 
 <13 years 42 Reference 67 Reference 150 Reference 
 14 years 48 0.85 (0.56-1.29) 79 0.83 (0.60-1.16) 230 1.07 (0.87-1.32) 
 ≥15 years 12 0.70 (0.36-1.34) 27 0.82 (0.52-1.30) 85 1.07 (0.81-1.40) 
 P for trend²     0.46     0.36     0.47 
 P for subtype heterogeneity3             0.24 
                     
 Menstrual Cycle Regularity 
 None or Irregular 5 0.69 (0.27-1.79) 10 1.01 (0.51-1.99) 30 1.06 (0.71-1.59) 
 < 26 days 17 0.76 (0.43-1.34) 36 1.17 (0.77-1.78) 89 1.09 (0.84-1.41) 
 27-29 days 47 Reference 63 Reference 173 Reference 
 30+ days 17 0.88 (0.50-1.54) 29 1.37 (0.88-2.15) 55 0.96 (0.70-1.30) 
 P for trend²     0.49     0.58     0.46 
 P for subtype heterogeneity3              0.39 
   
 Oral Contraceptive Use 
 Never 37 Reference 85 Reference 223 Reference 
 Ever 66 1.17 (0.74-1.84) 91 0.85 (0.60-1.20) 244 0.94 (0.76-1.16) 
 Duration ≤1 year  18 1.50 (0.83-2.72) 27 1.41 (0.89-2.22) 55 1.13 (0.83-1.54) 
 >1-4 years 17 1.11 (0.60-2.07) 25 1.02 (0.63-1.66) 57 0.98 (0.72-1.34) 
 5-9 years 15 1.11 (0.57-2.14) 12 0.53 (0.28-1.01) 54 0.96 (0.70-1.33) 
 >10 years 10 0.75 (0.35-1.61) 18 0.54 (0.31-0.94) 60 0.71 (0.51-0.97) 
 P for trend²     0.22     0.01     0.01 
 P for subtype heterogeneity3: Ever/Never            0.63 
 P for subtype heterogeneity3: Duration      0.22 
           Ever Full-Term Pregnancy 
   No 15 Reference 41 Reference 63 Reference 
 Yes 88 1.12 (0.59-2.13) 130 0.47 (0.33-0.69) 393 0.81 (0.61-1.06) 
 1 child 15 1.22 (0.56-2.70) 16 0.33 (0.18-0.59) 83 0.97 (0.69-1.35) 
 2 children 49 1.39 (0.69-2.79) 60 0.46 (0.30-0.70) 193 0.87 (0.65-1.17) 
 3+ children 19 0.70 (0.32-1.55) 48 0.53 (0.34-0.83) 108 0.67 (0.48-0.92) 
 P for trend²     0.18   
 
0.16   
 
0.01 
 P for subtype heterogeneity3: Parity, yes/no     
  
0.02 
 P for subtype heterogeneity3: Number of children     
 
 0.84 
                    
 History of Breast feeding4             
        No 12 Reference 23 Reference 62 Reference 
       Yes 69 1.02 (0.54-1.93) 93 0.67 (0.41-1.08) 302 0.85 (0.64-1.13) 
 P for subtype heterogeneity3             0.39 
                    
 History of Hysterectomy 
 No 87 Reference 137 Reference 329 Reference 
 Yes 8 1.06 (0.49-2.32) 10 0.79 (0.40-1.55) 34 0.85 (0.58-1.25) 
 P for subtype heterogeneity3             0.84 
  
  
  
 
  
Age at Menopause5 
≤48 years 13 Reference 22 Reference 84 Reference 
 49-50 years 5 0.52 (0.17-1.54) 26 1.66 (0.90-3.07) 66 0.99 (0.71-1.38) 
 51-54 years 4 0.57 (0.17-1.88) 17 1.53 (0.77-3.06) 57 1.23 (0.86-1.76) 
 >55 years 1 0.42 (0.05-3.49) 9 2.71 (1.17-6.30) 27 1.57 (0.99-2.47) 
 P for trend²     0.72     0.01     0.04 
 P for subtype heterogeneity3             0.21 
   
 Ever Use of Postmenopausal Hormones5 
 No 21 Reference 53 Reference 149 Reference 
 Yes 14 0.62 (0.33-1.03) 31 0.92 (0.56-1.51) 116 1.12 (0.85-1.48) 
 P for subtype heterogeneity3             0.49 
   
 Body Mass Index, kg/m2         
<25 62 Reference 96 Reference 270 Reference 
25-30 29 1.07 (0.68-1.70) 67 1.33 (0.95-1.84) 134 0.88 (0.71-1.09) 
≥30 15 1.52 (0.84-2.75) 19 0.82 (0.49-1.38) 71 1.10 (0.83-1.45) 
P for trend²  0.27   0.25   0.63 
P for subtype heterogeneity3       0.23 
1Stratified by age at recruitment and study center and adjusted for ever full-term pregnancy, ever OC use, 
menopausal status at recruitment, age at menopause, and ever HRT use 
²P for trend on continuous scale 
3P for subtype heterogeneity comparing type I and type II tumors. 
4Among parous women 
5Among postmenopausal women 
 
 
  
Table 3. Factors related to ovulatory lifespan and total ovulatory lifespan and risk of borderline tumors and  
invasive type I and type II epithelial ovarian cancer: EPIC cohort, 1992-2010 
 Borderline  
HR (95% CI)1 
Type I  
HR (95% CI)1 
Type II 
HR (95% CI)1 
 
phet
2 
Risk per year older age at menarche  0.94 (0.81-1.10) 0.95 (0.85-1.07) 1.02 (0.95-1.09) 0.34 
Risk per year younger age at menopause3,4 0.98 (0.89-1.08) 0.92 (0.86-0.98) 0.98 (0.95-1.01) 0.09 
Risk per year of OC use 0.96 (0.91-1.01) 0.97 (0.94-1.00) 0.97 (0.96-0.99) 0.73 
Risk per year of being pregnant5 0.84 (0.64-1.10) 0.78 (0.64-0.95) 0.84 (0.75-0.94) 0.53 
Risk per year reduction of total ovulatory lifespan6 0.96 (0.91-1.00) 0.95 (0.92-0.98) 0.97 (0.96-0.99) 0.17 
     
Restricted to Women Postmenopausal at Baseline     
Risk per year older age at menarche  1.14 (0.87-1.50) 1.13 (0.97-1.31) 1.07 (0.98-1.16) 0.54 
Risk per year younger age at menopause3 1.00 (0.91-1.11) 0.91 (0.85-0.97) 0.97 (0.94-1.00) 0.08 
Risk per year of OC use 0.94 (0.81-1.08) 0.98 (0.93-1.02) 0.99 (0.97-1.02) 0.53 
Risk per year of being pregnant5 1.01 (0.66-1.56) 0.88 (0.68-1.14) 0.88 (0.76-1.02) 0.97 
Risk per year reduction of total ovulatory lifespan7 0.99 (0.92-1.06) 0.96 (0.92-1.00) 0.99 (0.97-1.00) 0.19 
1Age and center stratified and further adjusted for menopausal status at recruitment, ever OC use and ever HRT use, and mutually adjusted for the risk 
factors presented in this table. 
2P for heterogeneity comparing type I and type II tumors. 
3Age at menopause was entered in the model with a minus sign to compare with other factors.  
4 For women not postmenopausal at recruitment, age at menopause was replaced by age at recruitment. 
5Calculated as: (number of FTP) x 0.75.  
6Calculated as: (age at menopause – age at menarche – duration of OC use – cumulative duration of FTP), and entered into the model with a minus sign; 
Age and center stratified and further adjusted for menopausal status at recruitment and ever HRT use. 
7Calculated as: (age at menopause – age at menarche – duration of OC use – cumulative duration of FTP), and entered into the model with a minus sign; 
Age and center stratified and adjusted for ever HRT use. 
 
  
Table 4: Reproductive and hormone-related factors and risk of invasive epithelial ovarian cancer overall and by main histologic subtypes: EPIC cohort, 1992-
2010 
  Invasive EOC  Serous Mucinous  Endometrioid     Clear Cell 
  (n=1,139)  (n=631) (n=79) (n=131)  (n=57) 
 Case Case Case Case  Case   
   n    HR1 95% CI    n    HR1 95% CI  n    HR1 95% CI   n     HR1 95% CI  n HR1 95% CI 
Age at Menarche           
  <13 years 366 Reference 197 Reference 27 Reference 45 Reference  26 Reference 
  14 years 515 0.96 (0.84-1.10) 302 1.04 (0.87-1.25) 30 0.78 (0.46-1.32) 57 0.84 (0.57-1.25)  20 0.52 (0.28-0.94) 
  ≥15 years 210 0.99 (0.83-1.18) 112 1.00 (0.79-1.27) 17 1.26 (0.67-2.38) 25 0.95 (0.57-1.57)  6 0.40 (0.16-0.98) 
     P for trend²                    0.99                     0.90                        0.52  0.83   0.01 
     P for subtype heterogeneity3                            0.08 
          
Menstrual Cycle Regularity          
  None or Irregular   66 0.86 (0.73-1.25)   39 1.03 (0.73-1.46)   6 1.47 (0.59-3.69)   9 1.25 (0.60-2.59)  1 0.25 (0.03-1.93) 
  ≤26 days 245 1.14 (0.97-1.33) 139 1.19 (0.96-1.47) 14 1.15 (0.58-2.24) 24 1.03 (0.62-1.68)  10 0.78 (0.37-1.66) 
  27-29 days 433 Reference 233 Reference 23 Reference 49 Reference  24 Reference 
  30+ days 159 1.19 (0.99-1.43)   88 1.19 (0.93-1.53) 12 1.61 (0.79-3.25) 13 0.84 (0.45-1.55)  8 1.03 (0.46-2.32) 
     P for trend²                    0.55                     0.95            0.86                     0.40   0.18 
     P for subtype heterogeneity3                            0.46 
            
Oral Contraceptive Use          
  Never 574 Reference 298 Reference 35 Reference 56 Reference  26 Reference 
  Ever 530 0.84 (0.73-0.96) 316 0.92 (0.77-1.10) 41 0.88 (0.53-1.47) 71 1.12 (0.75-1.67)  27 0.87 (0.47-1.63) 
  Duration <=1 year 122 1.02 (0.83-1.25)   75 1.13 (0.87-1.47)   7 0.89 (0.39-2.07) 14 1.15 (0.62-2.12)  11 2.15 (1.01-4.58) 
2-4 years 135 0.96 (0.78-1.17)   76 0.98 (0.75-1.28) 14 1.43 (0.73-2.81) 17 1.16 (0.65-2.07)  6 0.81 (0.32-2.09) 
5-9 years 116 0.88 (0.71-1.09)   70 0.96 (0.73-1.27)   7 0.75 (0.31-1.78) 18 1.35 (0.76-2.41)  2 0.31 (0.07-1.35) 
≥10 years 113 0.57 (0.45-0.70)   68 0.61 (0.46-0.82) 10 0.70 (0.32-1.51) 13 0.62 (0.32-1.20)  5 0.47 (0.17-1.32) 
     P for trend²                  < 0.01               <0.01                     0.15                     0.09   0.07 
     P for subtype heterogeneity3: Ever  OC use       0.82 
     P for subtype heterogeneity3: Duration of OC use                          0.86 
          
  
  
Ever Full-Term Pregnancy          
  No 182 Reference 91 Reference 17 Reference 20 Reference  15 Reference 
  Yes 905 0.68 (0.57-0.80) 518 0.73 (0.58-0.92) 58 0.53 (0.30-0.95) 102 0.65 (0.40-1.06)  34 0.34 (0.18-0.64) 
1 child 172 0.77 (0.62-0.95) 108 0.89 (0.67-1.18)   5 0.25 (0.09-0.68) 16 0.64 (0.32-1.26)  6 0.37 (0.14-0.98) 
2 children 436 0.71 (0.59-0.85) 239 0.71 (0.56-0.91) 29 0.56 (0.30-1.07) 56 0.82 (0.48-1.41)  15 0.32 (0.15-0.69) 
3+ children 279 0.61 (0.50-0.74) 161 0.64 (0.49-0.83) 22 0.64 (0.32-1.27) 29 0.62 (0.34-1.13)  11 0.33 (0.14-0.76) 
     P for trend²               <0.01           <0.01                0.78                 0.28   0.01 
     P for subtype heterogeneity: Parity, yes/no3       0.16 
     P for subtype heterogeneity: Number of pregnancies3       0.37 
            
History of Breast feeding4           
  No 126 Reference 72 Reference 11 Reference 10 Reference  4 Reference 
  Yes 718 0.93 (0.76-1.13) 413 0.95 (0.74-1.24) 39 0.59 (0.29-1.20) 87 1.25 (0.64-2.46)  27 0.96 (0.33-2.83) 
      P for subtype heterogeneity3                               0.51 
          
History of Hysterectomy          
  No 855 Reference 464 Reference 53 Reference 90 Reference  43 Reference 
  Yes   94 0.87 (0.69-1.10)   60 1.00 (0.74-1.34)   6 0.92 (0.37-2.32) 10 1.00 (0.50-2.01)  1 0.30 (0.04-2.28) 
     P for subtype heterogeneity3                           0.60 
          
Age at Menopause5           
  ≤48 years 192 Reference 108 Reference 12 Reference 20 Reference  5 Reference 
  49-50 years 175 1.18 (0.96-1.46)   97 1.11 (0.83-1.47) 11 1.18 (0.50-2.77) 14 1.00 (0.49-2.05)  12 3.47 (1.09-11.0) 
  51-54 years 139 1.30 (1.03-1.63)   77 1.20 (0.89-1.63)   6 0.85 (0.30-2.40) 14 1.43 (0.69-2.98)  6 2.73 (0.74-10.1) 
  ≥55 years   67 1.62 (1.21-2.17)   30 1.18 (0.77-1.79)   3 1.53 (0.40-5.82) 13 3.56 (1.63-7.76)  4 2.27 (1.45-27.1) 
     P for trend²                   <0.01  0.15  0.68  0.01   0.03 
     P for subtype heterogeneity3                          0.09 
            
Ever Use of Postmenopausal Hormones5          
  No 387 Reference 192 Reference 22 Reference 35 Reference  20 Reference 
  Yes 284 1.17 (0.98-1.39) 171 1.27 (1.01-1.60) 14 0.93 (0.44-1.94) 36 1.79 (1.07-3.01)  9 0.68 (0.29-1.63) 
     P for subtype heterogeneity3                          0.22 
 
 
 
 
 
 
 
          
  
Body Mass Index, kg/m2          
<25 604 Reference 358 Reference 39 Reference 64 Reference 27  Reference 
25-30 343 0.98 (0.85-1.12) 168 0.81 (0.67-0.98) 31 1.63 (1.00-2.67) 46 1.31 (0.89-1.94) 22 1.56 (0.86-2.83) 
≥30 173 1.14 (0.95-1.36) 98 1.12 (0.88-1.42) 8 1.00 (0.46-2.21) 17 1.23 (0.71-2.16) 7 1.04 (0.43-2.52) 
     P for trend²  0.07  0.92  0.36  0.22   0.21 
     P for subtype heterogeneity3                         0.49   
 
1Stratified by age at recruitment and study center and adjusted for ever full-term pregnancy, ever OC use, menopausal status at recruitment, age at 
menopause, and ever HRT use 
²P for trend on continuous scale 
3P for subtype heterogeneity comparing serous, mucinous, endometrioid, and clear cell tumors. 
4Among parous women 
5Among postmenopausal women 
 
 
  
  
Table 5. Factors related to ovulatory lifespan and total ovulatory lifespan and risk of invasive epithelial ovarian cancer overall and by main histologic 
subtypes: EPIC cohort, 1992-2010 
 
  
Invasive Serous  Mucinous Endometrioid  Clear Cell   
HR (95% CI)1  HR (95% CI)1 HR (95% CI)1  HR (95% CI)1 HR (95% CI)1 phet2 
 
Risk per year older age at menarche  1.01 (0.96-1.05) 1.00 (0.95-1.06) 1.06 (0.90-1.25) 1.00 (0.88-1.14) 0.77 (0.63-0.95) 0.10 
 
Risk per year younger age at menopause3,4 0.97 (0.95-0.99) 0.98 (0.96-1.01) 0.97 (0.89-1.06) 0.93 (0.87-0.99) 0.88 (0.78-0.99) 0.11 
 
Risk per year of OC use 0.97 (0.95-0.98) 0.97 (0.95-0.98) 0.98 (0.94-1.02) 0.97 (0.94-1.01) 0.96 (0.90-1.02) 0.92 
 
Risk per year of being pregnant5 0.83 (0.77-0.90) 0.85 (0.77-0.94) 0.88 (0.66-1.18) 0.78 (0.62-0.98) 0.56 (0.38-0.81) 0.17 
 
Risk per year reduction of total ovulatory lifespan6 0.97 (0.96-0.98) 0.97 (0.96-0.98) 0.98 (0.94-1.02) 0.96 (0.93-0.99) 0.91 (0.85-0.97) 0.18 
 
          
 
 Restricted to Women Postmenopausal at Baseline           
 Risk per year older age at menarche  1.05 (0.99-1.10) 1.03 (0.96-1.11) 1.34 (1.08-1.67) 1.08 (0.91-1.27) 0.88 (0.68-1.15) 0.08 
 
Risk per year younger age at menopause3 0.97 (0.95-0.98) 0.98 (0.95-1.00) 0.97 (0.88-1.06) 0.93 (0.87-1.00) 0.85 (0.75-0.97) 0.10 
 
Risk per year of OC use 0.98 (0.96-0.99) 0.98 (0.96-1.00) 1.01 (0.95-1.06) 0.98 (0.93-1.03) 0.94 (0.84-1.05) 0.67 
 
Risk per year of being pregnant5 0.87 (0.80-0.96) 0.90 (0.80-1.02) 0.94 (0.64-1.37) 0.80 (0.60-1.06) 0.51 (0.32-0.83) 0.13 
 
Risk per year reduction of total ovulatory lifespan7 0.97 (0.96-0.99) 0.98 (0.96-1.00) 1.01 (0.96-1.06) 0.96 (0.92-1.00) 0.87 (0.79-0.95) 0.02 
 
1Age and center stratified and further adjusted for menopausal status at recruitment, ever OC use and ever HRT use, and mutually adjusted for the risk factors presented 
in this table. 
2P for heterogeneity comparing serous, mucinous, endometrioid, and clear cell tumors. 
3Age at menopause was entered in the model with a minus sign to compare with other factors.  
4For women not postmenopausal at recruitment, age at menopause was replaced by age at recruitment.  
5Calculated as: (number of FTP) x 0.75.  
6Calculated as: (age at menopause – age at menarche – duration of OC use – cumulative duration of FTP), and entered into the model with a minus sign; Age and center 
stratified and further adjusted for menopausal status at recruitment and ever HRT use. 
7Calculated as: (age at menopause – age at menarche – duration of OC use – cumulative duration of FTP), and entered into the model with a minus sign; Age and center 
stratified and adjusted for ever HRT use. 
  
  
Supplemental Table 1. Pregnancy-related variables (mutually adjusted) and risk of borderline tumors and  
invasive type I and type II epithelial ovarian cancer among parous women: EPIC cohort, 1992-2010 
  Borderline Type I Type II 
  HR (95%CI)1 HR (95%CI) 1 HR (95%CI) 1 phet
2
Number of Full-Term Pregnancies 
   1 ref ref ref 
 2 1.11 (0.60-2.05) 1.30 (0.73-2.33) 1.02 (0.77-1.35) 
 3+ 0.59 (0.26-1.33) 1.33 (0.68-2.62) 0.86 (0.60-1.23) 
ptrend
3
 0.13 0.51 0.44  
   0.34 
Age at first pregnancy 
  
 <25 ref Ref ref 
 25-29 1.33 (0.80-2.23) 0.88 (0.58-1.35) 1.10 (0.86-1.41) 
 ≥30 0.77 (0.29-2.07) 0.73 (0.35-1.52) 1.37 (0.92-2.05) 
ptrend
3 0.83 0.17 0.03 
 
   0.02 
Age at last pregnancy 
  
 <29 ref ref ref 
 29-34 0.95 (0.50-1.81) 1.49 (0.90-2.44) 1.01 (0.75-1.36) 
 ≥35 1.08 (0.41-2.81) 1.56 (0.76-3.20) 0.84 (0.53-1.31) 
ptrend
3 0.20 0.19 0.87  
   0.31 
Time since last pregnancy 
  
 ≤20 ref ref Ref 
 21-25 1.26 (0.62-2.56) 1.33 (0.76-2.32) 1.03 (0.72-1.49) 
 26-30 1.52 (0.64-3.65) 0.97 (0.48-1.95) 1.50 (1.00-2.25) 
 >30 1.40 (0.43-4.54) 1.43 (0.64-3.23) 1.41 (0.85-2.34) 
 ptrend
3 0.21 0.41 0.41 
    0.82 
1Stratified by age at recruitment and study center and adjusted for ever OC use, menopausal status at recruitment ,  
age at menopause, and ever HRT use, and all other pregnancy-related variables in the table 
2P for subtype heterogeneity comparing type I and type II tumors 
3P for trend on continuous scale 
 
 
  
Supplemental Table 2. Pregnancy-related variables (mutually adjusted) and risk of invasive epithelial ovarian cancer overall and by main histologic 
subtypes among parous women: EPIC cohort, 1992-2010 
  Invasive Serous Mucinous Endometrioid Clear Cell 
  HR (95%CI)1 HR (95%CI)1 HR (95%CI)1 HR (95%CI)1 HR (95%CI)1 phet
2 
Number of Full-Term 
Pregnancies    
 
 1 ref ref ref ref ref 
 2 0.97 (0.80-1.17) 0.89 (0.70-1.14) 2.58 (0.97-6.87) 1.26 (0.69-2.31) 0.53 ( 0.19-1.49) 
 3+ 0.84 (0.67-1.07) 0.87 (0.64-1.17) 2.96 (0.98-8.89) 0.89 (0.42-1.88) 0.38 ( 0.11-1.36)  
ptrend
3 0.32 0.56 0.03 0.55 0.09 
 
     
 0.05 
Age at first pregnancy 
   
 
 <25 ref ref ref ref Ref 
 25-29 0.95 (0.81-1.12) 0.97 (0.78-1.21) 0.96 (0.50-1.88) 1.17 (0.74-1.86) 0.70 ( 0.32-1.55) 
 ≥30 1.07 (0.82-1.40) 1.38 (0.97-1.95) 1.54 (0.57-4.17) 0.73 (0.32-1.69) 0.09 ( 0.01-0.86)  
ptrend
3 0.88 0.13 0.95 0.89 0.13 
 
     
 0.30 
Age at last pregnancy 
   
 
 <29 ref ref ref ref Ref 
 29-34 1.13 (0.94-1.38) 1.13 (0.88-1.47) 1.08 (0.50-2.33) 1.08 (0.62-1.88) 1.80 ( 0.68-4.78) 
 ≥35 0.96 (0.71-1.28) 0.87 (0.59-1.30) 1.68 (0.60-4.75) 1.21 (0.53-2.75) 0.65 ( 0.11-3.92)  
ptrend
3 0.97 0.74 0.25 0.46 0.90 
 
     
 0.61 
Time since last pregnancy 
   
 
 ≤20 ref ref ref ref Ref 
 21-25 1.06 (0.83-1.35) 1.12 (0.81-1.55) 1.12 (0.46-2.73) 0.89 (0.45-1.77) 1.48 ( 0.52-4.21) 
 26-30 1.27 (0.97-1.66) 1.62 (1.13-2.31) 1.31 (0.48-3.59) 0.71 (0.32-1.59) 0.26 ( 0.05-1.26) 
 >30 1.32 (0.96-1.83) 1.64 (1.05-2.54) 1.65 (0.49-5.63) 0.77 (0.30-1.99) 0.59 ( 0.12-2.82)  
ptrend
3  0.21 0.09 0.52 0.80 0.24 
 
      0.35 
1Stratified by age at recruitment and study center and adjusted for ever OC use, menopausal status at recruitment, age at menopause, and ever HRT use, and 
all other pregnancy-related variables in the table 
2P for subtype heterogeneity comparing serous, mucinous, endometrioid, and clear cell subtypes 
3P for trend on continuous scale 
 
 
